AB5352
Anti-Amyloid Precursor Protein Antibody, CT
serum, Chemicon®
Synonym(s):
APP
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human, monkey
manufacturer/tradename
Chemicon®
technique(s)
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... APP(351)
Specificity
Recognizes Amyloid Precursor Protein (APP), C-terminal. Recognizes full length APP and C-terminal fragments resulting from cleavage by secretase. May react with APLP1 and APLP2.
Immunogen
Epitope: C-terminus
Nine amino acid peptide from the C-terminus of APP (YKFFEQMQN)
Application
Detect Amyloid Precursor Protein using this Anti-Amyloid Precursor Protein Antibody, C-terminus validated for use in IC, IH, IP & WB.
Immunohistochemistry: 1:100-1:400
Immunocytochemistry on NTera2 and COS cell lines: 1:100-1:400
Western blot: 1:500-1:2000: The low abundance of full length APP in untreated cells means that poor response is seen with immunoblotting of whole cell lysates. We recommend that membrane fractions be prepared to increase the loading of APP as well as remove potential interferences from soluable proteins. NTera2, Cos7 and Hela cell membrane preparations are positive by western blots.
Immunoprecipitation: 1:100-1:400.
Optimal working dilutions must be determined by end user.
Immunocytochemistry on NTera2 and COS cell lines: 1:100-1:400
Western blot: 1:500-1:2000: The low abundance of full length APP in untreated cells means that poor response is seen with immunoblotting of whole cell lysates. We recommend that membrane fractions be prepared to increase the loading of APP as well as remove potential interferences from soluable proteins. NTera2, Cos7 and Hela cell membrane preparations are positive by western blots.
Immunoprecipitation: 1:100-1:400.
Optimal working dilutions must be determined by end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Physical form
Serum. Liquid in PBS with 0.02% azide.
Unpurified
Storage and Stability
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Analysis Note
Control
Brain
Brain
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
GGA proteins mediate the recycling pathway of memapsin 2 (BACE).
He, X; Li, F; Chang, WP; Tang, J
The Journal of Biological Chemistry null
Virgil Muresan et al.
Neuro-degenerative diseases, 13(2-3), 122-125 (2013-09-07)
The pathology of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder affecting motor neurons, comprises aberrant accumulations of neurofilaments; mutations in the peripherin subunit of neurofilaments have been identified in some forms of ALS. Recently, the amyloid-β precursor protein (APP), a
R van Dijk et al.
Journal of neurochemistry, 90(3), 712-723 (2004-07-17)
Frame-shifted amyloid precursor protein (APP(+1)), which has a truncated out-of-frame C-terminus, accumulates in the neuropathological hallmarks of patients with Alzheimer's disease pathology. To study a possible involvement of APP(+1) in the pathogenesis of Alzheimer's disease, we expressed APP695 and APP(+1)
A Kamal et al.
Neuron, 28(2), 449-459 (2001-01-06)
We analyzed the mechanism of axonal transport of the amyloid precursor protein (APP), which plays a major role in the development of Alzheimer's disease. Coimmunoprecipitation, sucrose gradient, and direct in vitro binding demonstrated that APP forms a complex with the
Chun-Yan Wang et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 36(5), 1073-1089 (2011-02-04)
Huperzine A (HupA) is a reversible and selective inhibitor of acetylcholinesterase (AChE), and it has multiple targets when used for Alzheimer's disease (AD) therapy. In this study, we searched for new mechanisms by which HupA could activate Wnt signaling and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service